San Diego, CA, United States of America

Forge Therapeutics, Inc.


USPTO Granted Patents = 5

% Expired Patents = 60.0


Forward Citations = 18

Loading Chart...
Loading Chart...

12 inventors (with patents filed for the assignee):

goldMedal Baskar Nammalwar (5 out of 10 patents)

silverMedal David Thomas Puerta (5 out of 36 patents)

bronzeMedal Min Teng (5 out of 94 patents)

4.  Konstantin Taganov (4 out of 10 patents)

5.  Xiaoming Li (2 out of 19 patents)

6.  Christian Perez (1 out of 3 patents)

7.  Ian Yule (1 out of 5 patents)

8.  Adele Faulkner (1 out of 2 patents)

9.  Holly Atton (1 out of 8 patents)

10.  Alastair Parkes (1 out of 2 patents)

11.  Serge Convers-Reignier (1 out of 5 patents)

12.  Michelle Southey (1 out of 2 patents)


5 patents:

Company Overview
Forge Therapeutics, Inc. is a biotechnology company developing novel antibiotics to combat multi-drug resistant bacteria. The company's innovative platform combines cutting-edge chemistry and bioinformatics to develop breakthrough treatments for infectious diseases. Forge Therapeutics is dedicated to addressing the urgent global health threat posed by antibiotic resistance through its groundbreaking research and development efforts.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Forge Therapeutics, Inc. USPTO Patent Assignee Logo
5 Patents

#875 in San Diego, CA

#12,070 in California

#51,620 in US

San Diego, CA (US)
San Diego, CA, United States of America
Forward Citations = 18

12 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Forge Therapeutics, Inc.. Retrieved from https://idiyas.com/company/forge-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…